A NEW APPROACH TO THE TREATMENT OF DIABETIC NEPHROPATHY WITH HEART FAILURE
Keywords:
chronic kidney disease, type 2 sodium-glucose cotransporter inhibitorsAbstract
The development of chronic kidney disease (CKD) is a risk factor not only for the formation of cardiovascular diseases, but also for chronic heart failure (CHF). The article is a literature review on the problem of the use of sodium-glucose cotransporter type 2 inhibitors (NGLT2) in patients with CKD and CHF. The article presents in detail the mechanisms of action of NGL-2 inhibitors in the light of reno- and cardioprotection. In addition to the glucosuric effect of NGLT2 inhibitors, they have a natriuretic and diuretic effect. One of the effects of NGL-2 inhibitors is the ability to lower blood pressure. Another effect of NGLT2-2 inhibitors, explaining their renoprotective effect, is the effect on glomerular filtration.
References
Kolegova I.I., Chernyavina A.I. I., Kozio-Lova N.A. Characteristics of the course of chronic heart failure and the state of target organs in patients with cardiorenal syndrome. Russian Journal of Cardiology. 2018;(1):21-26. https://doi.org/10.15829/1560-4071-2018-1-21-26.
Chen S, Hsu WY, Lin YN, et al. Incidence and risk of major adverse cardiovascular events in middle-aged patients with chronic kidney disease: a population-based cohort study. Int Urol Nephrol. 2019;51(7):1219-27. https://doi.org/10.1007/s11255-019-02157-7.
Rossetti L, Smith D, Shulman GI, et al. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest. 1987;79(5):1510-5. https://doi.org/10.1172/JCI112981.
Nespoux J, Vallon V. Renal effects of SGLT2 inhibitors: an update. Curr Opin Nephrol Hypertens. 2020;29(2):190-8. https://doi.org/10.1097/MNH.0000000000000584.
Vallon V, Thomson SC. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia. 2017;60(2):215-25. https://doi.org/10.1007/s00125-016-4157-3.
Wilcox CS. Antihypertensive and Renal Mechanisms of SGLT2 (Sodium-Glucose Linked Transporter 2) Inhibitors. Hypertension. 2020;75(4):894-901. https://doi.org/10.1161/hypertensionaha.119.11684.
Heersprink LHJ, de Zeeuw D, Wie L, et al. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes. Metab. 2013;15(9):853-62. https://doi.org/10.1111/dom.12127.
Vestri S, Okamoto MM, de Freitas HS, et al. Changes in sodium or glucose filtration rate modulate expression of glucose transporters in renal proximal tubular cells of rat. J. Membr. Biol. 2001;182(2):105-12. https://doi.org/10.1007/s00232-001-0036-y.
Silva Dos Santos D, Polidoro JZ, Borges-Junior FA, Girardi ACC. Cardioprotection conferred by sodium-glucose cotransporter 2 inhibitors: a renal proximal tubule perspective. Am J Physiol Cell Physiol. 2020;318(2):328-36. https://doi.org/10.1152/ajpcell.00275.2019.
Pessoa TD, Campos LC, Carraro-Lacroix L, et al. Functional role of glucose metabolism, osmotic stress, and sodium-glucose cotransporter isoform-mediated transport on Na+/ H+ exchanger isoform 3 activity in the renal proximal tubule. J Am Soc Nephrol. 2014;506(25):2028-39. https://doi.org/10.1681/ASN.2013060588.
Coady MJ, El Tarazi A, Santer R, et al. MAP17 Is a Necessary Activator of Renal Na+/ Glucose Cotransporter SGLT2. J Am Soc Nephrol. 2017;28(1):85-93. https://doi.org/10.1681/ASN.2015111282.
Pribanic S, Gisler SM, Bacic D, et al. Interactions of MAP17 with the NaPi-IIa/PDZK1 protein complex in renal proximal tubular cells. Am J Physiol Renal Physiol. 2003;285(4):F784-91. https://doi.org/10.1152/ajprenal.00109.2003.
Thomson R, Wang T, Thomson B, et al. Role of PDZK1 in membrane expression of renal brush border ion exchangers. Proceedings of the Nat Acad of Sci of the USA. 2005;102(37):13331-6. https://doi.org/10.1073/pnas.0506578102.
McGurnaghan SJ, Brierley L, Caparrotta TM, et al. The effect of dapagliflozin on glycaemic control and other cardiovascular disease risk factors in type 2 diabetes mellitus: a real-world observational study. Diabetologia. 2019;62(4):621-32. https://doi.org/10.1007/s00125-018-4806-9.
Baker WL, Buckley LF, Kelly MS, et al. Effects of Sodium-Glucose Cotransporter 2 Inhibitors on 24-Hour Ambulatory Blood Pressure: A Systematic Review and MetaAnalysis. J Am Heart Assoc. 2017;6(5):005686. https://doi.org/10.1161/JAHA.117.005686.
